Eric Crombez - May 1, 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role: EVP and Chief Medical Officer
Signature: /s/ Karah Parschauer, attorney-in-fact
Stock symbol: RARE
Transactions as of: May 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 5/2/2023, 06:18 PM
Next filing: Sep 29, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RARE	Common Stock	Award	$0	+4.66K	+18.02%	$0.00	30.5K	May 1, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RARE	Stock Option (Right to Buy)	Award	$0	+8.36K		$0.00	8.36K	May 1, 2023	Common Stock	8.36K	$44.03	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
F2	Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3	The option shall vest with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares initially subject to the option shall continue to vest on each month such that the option will fully vest on the fourth anniversary of the grant date.